Abvc Biopharma Inc - ABVC STOCK NEWS

ABVC BioPharma (NASDAQ: ABVC) has received a $200,000 initial cash payment from OncoX BioPharma as part of a strategic licensing agreement for oncology-related products. This payment represents the first installment of a potential $5 million in licensing fees from OncoX. The company has now accumulated $546,000 in total cash payments from three strategic partners.

Under the agreement, ABVC and its subsidiaries BioLite Inc. and Rgene can each receive up to 10M OncoX shares, $5M in cash payments, and royalties up to $50M post-product launch. The partnership aims to advance breakthrough therapies in oncology, targeting a market projected to reach $393.61 billion by 2032 with a 9.20% CAGR.

ABVC BioPharma reported significant Q3 2024 financial improvements, achieving its first operational profit. Revenue increased to $389,276 from $15,884 in Q3 2023. Net loss decreased to $134,272 from $3.37 million, with EPS improving to $(0.02) from $(0.82). The company secured multiple licensing agreements, including partnerships with ForSeeCon Eye for Vitargus®, potentially generating $187 million. Clinical developments include completed Phase II trials for ABV-1504 in Major Depressive Disorder and ongoing Phase IIb trials for ADHD. Cash position improved to $137,344, with shareholders' equity at $7.98 million.

ABVC BioPharma has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., bringing the total payments from strategic partners to $346,000. This payment is part of a broader agreement related to ABVC's psychiatric disorder pipeline, which includes treatments for Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD). The pipeline is valued at $667M by third-party evaluators.

ABVC has received 23M AiBtl shares as part of the first milestone and will obtain royalties up to $100M after product launch. The company is positioned in growing markets, with the global MDD market projected to reach $14.96 billion by 2032 and the global ADHD treatment market expected to grow at a CAGR of 7.3% through 2032. The global botanical drug market is forecasted to reach $3.2 billion by 2030 with a CAGR of 39%.

ABVC BioPharma (NASDAQ: ABVC) reported strong Q2 2024 financial results and strategic achievements. Key highlights include:

1. Executed global licensing agreements potentially providing up to $292 million in income
2. Received $116,000 in cash milestone income
3. Improved EPS by 86.8% year-over-year to -$0.09
4. Increased revenue to $117,142, up from $6,109 in Q2 2023
5. Maintained $7.8 million in shareholders' equity
6. Obtained multiple patents and FDA approvals for treatments in major depressive disorder, ADHD, and ophthalmology
7. Completed Phase II trials for MDD and initiated Phase IIb trials for ADHD

ABVC is focusing on advancing its pipeline, expanding partnerships, and driving sustainable growth in oncology/hematology, CNS, and ophthalmology.

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the acquisition of TT Life Company by its subsidiary AiBtl BioPharma Inc. for $8.33M, with 1.66M AiBtl shares exchanged at $5 per share. The strategic move aims to expand AiBtl's portfolio in precision medicine, leveraging TT Life's manufacturing capabilities. This acquisition will enhance AiBtl's global presence and innovation in AI-integrated products for consumer wellness.

ABVC BioPharma, Inc. (NASDAQ: ABVC) has signed a global licensing agreement with OncoX for the treatment of NSCLC, expecting an aggregate income of $13.75M and royalties of up to $12.50M. The agreement covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's single-herb botanical drug extract from the dry fruit body of Maitake Mushroom for NSCLC treatment. ABVC and its affiliate will receive a license fee of $12.5M in cash or shares, with additional milestone payments and royalties. The collaboration aims to accelerate the availability of the treatment worldwide, leveraging the strengths of both companies.

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced a potential licensing deal with OncoX BioPharma, Inc. for its Oncology/Hematology pipeline, involving $50M in licensing fees, milestone payments, and royalties. The company has FDA-approved INDs for various cancer treatments using innovative active ingredients. The partnership aims to revolutionize the sector and create significant value for stakeholders.

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced a global licensing agreement with ForSeeCon Eye for its Ophthalmology pipeline, including the medical device Vitargus® valued at $187M. The deal covers clinical trials, registration, manufacturing, supply, and distribution rights, with ABVC receiving $30M upfront and potential milestones. The partnership aims to enhance patient care and revenue generation, with ABVC continuing as R&D partner for new ophthalmic products.

ABVC BioPharma, Inc. announces an agreement for the exchange of real estate for AIBL stock, valued at $7.6 million. The deal involves 1,533,333 shares at $5 per share, benefiting ABVC and its subsidiary BioLite, Inc. The transaction is expected to bring significant value to the assets and reduce manufacturing costs for drug products.